103790-49-4

Upstream product

• 2581-34-2 3-methyl-4-nitrophenol 
• 107-07-3 2-chloro-ethanol 
• 540-51-2 2-bromoethanol 

Downstream Products

• 103790-50-7 4-(2-hydroxyethoxy)-2-methylaniline 
• 1402056-85-2 isopropyl 5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-{[4-(2-hydroxyethoxy)-2-methylphenyl]amino}-4-oxo-4,5-dihydrofuran-3-carboxylate 
• 1402056-84-1 n-butyl 5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-{[4-(2-hydroxyethoxy)-2-methylphenyl]amino}-4-oxo-4,5-dihydrofuran-3-carboxylate 
• 1402056-79-4 cyclopropylmethyl 5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-{[4-(2-hydroxyethoxy)-2-methylphenyl]amino}-4-oxo-4,5-dihydrofuran-3-carboxylate 
• 1402055-93-9 ethyl 5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-{[4-(2-hydroxyethoxy)-2-methylphenyl]amino}-4-oxo-4,5-dihydrofuran-3-carboxylate 
• 873453-79-3 tert-butyldimethyl[2-(3-methyl-4-nitrophenoxy)ethoxy]silane 
• 103790-12-1 4-Methyl-N-[7-methyl-1,4-dioxa-spiro[4.5]deca-6,9-dien-(8Z)-ylidene]-benzenesulfonamide 
• 103790-19-8 2-<3-methyl-4-(p-toluenesulphonamido)phenoxy>ethanol 

Relevant academic research and scientific papers

NOVEL FURANONE DERIVATIVE

To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I): wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon grou

UREA DERIVATIVE

The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R 2 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.

The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.

A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation. Their selectivity for the 5-HT4 receptor was established by examining their affinity for other 5-HT receptors using radioligand-binding techniques. Several selective and highly potent full as well as partial agonists emerged from this study. For example, 1b,d were found to be the most potent, full 5-HT4 receptor agonist described so far (EC50 = 0.5 and 0.8 nM, respectively), being 6 and 4 times more potent than serotonin itself. On the other hand, 5b and 1h appeared as partial 5-HT4 receptor agonists in the nonstimulated guinea pig ileum preparation with potencies, evaluated against serotonin action, respectively similar (5b, Ki = 12 nM) to and 300-fold higher (1h, Ki = 0.04 nM) than serotonin.

Spirodienones. Part 5. The Synthesis and Reactions of N-Sulphonylcyclohexadienimines

The anodic or chemical oxidation of para-substituted sulphonanilides gives 4,4-disubstituted N-sulphonylcyclohexadienimines, which, from appropriately substituted anilines, may be spirocyclic.The scope and limitations of the synthesis are described, and mechanism proposed.The selective hydrolysis of the dienimines to the corresponding dienones provides a convenient route to the latter compounds.The reaction of some of the dienimines with dienes is discussed.